Studio per valutare il mantenimento dell'efficacia durante la transizione dalla terapia anti-cluster di differenziazione 20 (CD20) a ublituximab (ENHANCE)
Valutazione del mantenimento dell'efficacia durante la transizione dalla terapia anti-CD20 a ublituximab
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: TG Therapeutics Clinical Support Team
- Numero di telefono: 1-877-575-8489
- Email: clinicalsupport@tgtxinc.com
Luoghi di studio
-
-
-
Bydgoszcz, Polonia, 85-796
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Katowice, Polonia, 40-555
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Kielce, Polonia, 25-726
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Krakow, Polonia, 31-826
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Lodz, Polonia, 90-324
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Polonia, 10-561
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Poznan, Polonia, 61-583
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Warsaw, Polonia, 04-141
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Zabrze, Polonia
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Żory, Polonia, 44-240
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35209
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Cullman, Alabama, Stati Uniti, 35058
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
California
-
Orange, California, Stati Uniti, 92697
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Fort Collins, Colorado, Stati Uniti, 80528
- Reclutamento
- TG Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30309
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Savannah, Georgia, Stati Uniti, 31406
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46256
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Overland Park, Kansas, Stati Uniti, 66212
- Completato
- TG Therapeutics Investigational Trial Site
-
Overland Park, Kansas, Stati Uniti, 66205
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Maryland
-
Lutherville, Maryland, Stati Uniti, 21093
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 70809
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Boston, Massachusetts, Stati Uniti, 00002
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Foxborough, Massachusetts, Stati Uniti, 02035
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
North Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Wellesley, Massachusetts, Stati Uniti, 02481
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Farmington, Michigan, Stati Uniti, 48334
- Reclutamento
- TG Investigational Site
-
-
Minnesota
-
Golden Valley, Minnesota, Stati Uniti, 55422
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Plymouth, Minnesota, Stati Uniti, 55446
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63131
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
New York
-
New York, New York, Stati Uniti, 10025
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
New York, New York, Stati Uniti, 11021
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Reclutamento
- TG Therapeutics Investigational Trial SiteCharlotte
-
Raleigh, North Carolina, Stati Uniti, 27607
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45212
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Dayton, Ohio, Stati Uniti, 45417
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37922
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Completato
- TG Therapeutics Investigational Trial Site
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84103
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Virginia
-
Vienna, Virginia, Stati Uniti, 22182
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Kirkland, Washington, Stati Uniti, 98034
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
Spokane, Washington, Stati Uniti, 99208
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- TG Therapeutics Investigational Trial Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Diagnosis of RMS (2017 Revised McDonald criteria).
-
Participants must meet one of the following prior treatment definitions:
- Participants naïve to treatment.
- Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
-
Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
-
Neurologically stable for > 30 days prior to first dose of ublituximab.
-
Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
-
Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
-
Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience
Exclusion Criteria:
- History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
- Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
- Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
- Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
- Previous serious opportunistic or atypical infection.
- Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
- History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
- Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
- Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
- Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
- Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).
Note: Other Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part A: Ublituximab
Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24. With Protocol Version 6.0, enrollment in Part A was closed. |
Administered as an intravenous (IV) infusion.
Altri nomi:
|
|
Sperimentale: Part B: Ublituximab /Placebo (Treatment Arm A)
Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
IV infusion Administered as an intravenous (IV) infusion.
Altri nomi:
|
|
Sperimentale: Part B: Ublituximab (Treatment Arm B)
Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
Administered as an intravenous (IV) infusion.
Altri nomi:
|
|
Sperimentale: Part C: Ublituximab (Treatment Arm C)
Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24. |
Administered as an intravenous (IV) infusion.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parte B: Area sotto la curva nelle prime 16 settimane (AUC0-W16) di Ublituximab
Lasso di tempo: Prima della dose e a più punti temporali fino alla settimana 16
|
Prima della dose e a più punti temporali fino alla settimana 16
|
|
|
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
Lasso di tempo: Baseline up to Week 48
|
The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique. |
Baseline up to Week 48
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
Lasso di tempo: Week 48
|
The Gd-enhancing T1 lesions will be evaluated using MRI technique. |
Week 48
|
|
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
Lasso di tempo: Up to Week 48
|
IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator. |
Up to Week 48
|
|
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
Lasso di tempo: Part A: Baseline, Week 24 and Week 48
|
The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness. |
Part A: Baseline, Week 24 and Week 48
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- TG1101-RMS401
- 2024-519284-18-00 (Altro identificatore: EU CT Number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .